Relationship Between Corpus Callusom Index and Clinical Subtypes, Severity of Cognitive Disorders, and Disability in Multiple Sclerosis
Novelty in Biomedicine,
Vol. 13 No. 1 (2025),
20 January 2025
,
Page 28-33
https://doi.org/10.22037/nbm.v13i1.46320
Abstract
Background: Brain magnetic resonance imaging (MRI) is crucial to determine the prognosis of multiple sclerosis (MS). The use of simple and accessible techniques that can be used for examining and managing the cognitive status and disability of patients with MS is one of the important concerns. This study aimed to investigate the relationship between corpus callosum index in brain MRI and clinical subgroups of MS, severity of cognitive disorders, and disability in multiple sclerosis.
Materials and Methods: This cross-sectional study was conducted to determine the relationship between CCI and clinical subgroups of MS, the severity of cognitive disorders, and disability in patients with MS referred to Imam Hossein Hospital in 2020. The maximum length of the corpus callosum (anterior, posterior diameter) was measured, and the height of the corpus callosum was measured on a line perpendicular to its long axis. Corpus callosum index (CCI), symbol digit modalities test (SDMT), and expanded disability status scale (EDSS) were assessed in patients. A significance level of less than 0.05 was considered.
Results: A total of 85 patients with a mean age of 40.73 ± 8.45 years were assessed, and 65.9% were women. The CCI value was significantly lower in women (P-value: 0.001). The mean value of EDSS in all participants was 2.64±2.49. There was a statistically significant difference between the different subgroups of MS with the EDSS score, age of disease onset, SDMT score, CCI index, and mean disease duration (all P-values<0.05). There was a significant negative correlation between the CCI index and age (P:0.02, r:-0.24), duration of the disease (P:0.001, r:-0.38), EDSS (P:0.001, r:-0.71), while the correlation between SDMT and CCI was positive (P:0.001, r:0.67).
Conclusion: CCI is a quick and cost-beneficial parameter to evaluate cognitive disorders and disability in patients with MS.
- Multiple sclerosis
- Corpus callosum
- Magnetic resonance imaging
How to Cite
References
Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. The Lancet. 2017;389(10076):1336-46.
Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nature Reviews Immunology. 2015;15(9):545-58.
Howard J, Trevick S, Younger DS. Epidemiology of multiple sclerosis. Neurologic clinics. 2016;34(4):919-39.
Garg N, Reddel SW, Miller DH, et al. The corpus callosum in the diagnosis of multiple sclerosis and other CNS demyelinating and inflammatory diseases. Journal of Neurology, Neurosurgery & Psychiatry. 2015;86(12):1374-82.
Cheong WL, Mohan D, Warren N, Reidpath DD. Multiple sclerosis in the Asia Pacific region: a systematic review of a neglected neurological disease. Frontiers in neurology. 2018;9:432.
Sumowski JF, Benedict R, Enzinger C, et al. Cognition in multiple sclerosis: State of the field and priorities for the future. Neurology. 2018;90(6):278-88.
Estiasari R, Fajrina Y, Lastri DN, et al. Validity and reliability of brief international cognitive assessment for multiple sclerosis (BICAMS) in Indonesia and the correlation with quality of life. Neurology research international. 2019;2019(1):4290352.
Firat A, Tascioglu A, Demiryurek M, et al. Evaluation of corpus callosum morphometry in patients with mesial temporal lobe epilepsy with hippocampal sclerosis. Surgical and Radiologic Anatomy. 2014;36:47-54.
Matthews PM, Roncaroli F, Waldman A, et al. A practical review of the neuropathology and neuroimaging of multiple sclerosis. Practical neurology. 2016;16(4):279-87.
Sugijono SE, Mulyadi R, Firdausia S, Prihartono J, Estiasari R. Corpus callosum index correlates with brain volumetry and disability in multiple sclerosis patients. Neurosciences Journal. 2020;25(3):193-9.
Granberg T, Martola J, Bergendal G, et al. Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: results of a 17-year longitudinal study. Multiple Sclerosis Journal. 2015;21(9):1151-8.
Papathanasiou A, Messinis L, Zampakis P, Papathanasopoulos P. Corpus callosum atrophy as a marker of clinically meaningful cognitive decline in secondary progressive multiple sclerosis. Impact on employment status. Journal of Clinical Neuroscience. 2017;43:170-5.
Dobson R, Giovannoni G. Multiple sclerosis–a review. European journal of neurology. 2019;26(1):27-40.
Yaldizli Ö, Atefy R, Gass A, et al. Corpus callosum index and long-term disability in multiple sclerosis patients. Journal of neurology. 2010;257:1256-64.
Benedict RH, DeLuca J, Phillips G, et al. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Multiple Sclerosis Journal. 2017;23(5):721-33.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444.
Demir A, Eren F, Yılmaz SE, İslamoğlu N. The Relationship Between Structural Measurements of the Corpus Callosum and Disability in Patients with Multiple Sclerosis. Genel Tıp Dergisi. 2022;32(4):433-8.
Yaldizli Ö, Penner I-K, Frontzek K, et al. The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients. Multiple Sclerosis Journal. 2014;20(3):356-64.
Caligiuri ME, Barone S, Cherubini A, et al. The relationship between regional microstructural abnormalities of the corpus callosum and physical and cognitive disability in relapsing–remitting multiple sclerosis. NeuroImage: Clinical. 2015;7:28-33.
Llufriu S, Blanco Y, Martinez-Heras E, et al. Influence of corpus callosum damage on cognition and physical disability in multiple sclerosis: a multimodal study. PloS one. 2012;7(5):e37167.
Akaike S, Okamoto T, Kurosawa R, et al. Exploring the Potential of the Corpus Callosum Area as a Predictive Marker for Impaired Information Processing in Multiple Sclerosis. Journal of Clinical Medicine. 2023;12(21):6948.
Fujimori J, Uryu K, Fujihara K, Wattjes MP, Suzuki C, Nakashima I. Measurements of the corpus callosum index and fractional anisotropy of the corpus callosum and their cutoff values are useful to assess global brain volume loss in multiple sclerosis. Multiple sclerosis and related disorders. 2020;45:102388.
Figueira FFA, Santos VSd, Figueira GMA, Silva ÂCMd. Corpus callosum index: a practical method for long-term follow-up in multiple sclerosis. Arquivos de neuro-psiquiatria. 2007;65:931-935.
Mesaros S, Rocca M, Kacar K, et al. Diffusion tensor MRI tractography and cognitive impairment in multiple sclerosis. Neurology. 2012;78(13):969-75.
- Abstract Viewed: 44 times
- pdf Downloaded: 50 times